- $14.29m
- $4.16m
Annual balance sheet for IN8bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Short Term Investments | 17.9 | 37 | 18.2 | 21.3 | 11.1 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 18.1 | 39 | 22.2 | 24.6 | 12.6 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.186 | 2.83 | 10.3 | 8.57 | 7.83 |
Other Long Term Assets | |||||
Total Assets | 20.9 | 42.2 | 33 | 33.7 | 20.9 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Current Liabilities | 2.57 | 2.26 | 5.82 | 5.39 | 3.08 |
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Liabilities | 2.59 | 4.04 | 10.3 | 8.77 | 6.47 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | 18.3 | 38.2 | 22.7 | 24.9 | 14.5 |
Total Liabilities & Shareholders' Equity | 20.9 | 42.2 | 33 | 33.7 | 20.9 |
Total Common Shares Outstanding |